$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000114420416087506 Filed on March 11, 2016

Income Statement

Concept	2016 Q1	2015	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.820M	$12.39M	$1.090M
YoY Change	91.84%	225.2%	179.49%
% of Gross Profit
Research & Development	$4.192M	$15.47M	$1.690M
YoY Change	74.81%	301.92%	201.79%
% of Gross Profit
Depreciation & Amortization	$270.0K	$1.000M	$70.00K
YoY Change	42.11%	900.0%	600.0%
% of Gross Profit
Operating Expenses	$7.010M	$27.86M	$4.870M
YoY Change	32.31%	131.38%	-57.65%
Operating Profit	-$7.010M	-$27.86M
YoY Change	32.31%	131.38%
Interest Expense	$130.0K	$200.0K	$0.00
YoY Change		-3633.57%
% of Operating Profit
Other Income/Expense, Net		$200.0K
YoY Change		3233.33%
Pretax Income	-$6.880M	-$27.66M	-$4.870M
YoY Change	29.81%	129.93%	-57.65%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.884M	-$27.66M	-$4.651M
YoY Change	29.94%	129.83%	-59.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$141.7K	-$622.8K	-$176.3K
COMMON SHARES
Basic Shares Outstanding	48.57M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.20M	$103.7M	$44.90M
YoY Change	-10.87%	130.96%	127.92%
Cash & Equivalents	$38.92M	$33.60M	$44.91M
Short-Term Investments	$60.30M	$70.10M
Other Short-Term Assets	$200.0K	$300.0K	$100.0K
YoY Change	100.0%	200.0%	-50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$99.36M	$104.0M	$44.98M
YoY Change	-10.82%	131.11%	126.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.409M	$1.700M	$1.532M
YoY Change	-33.8%	13.33%	5419.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.409M	$1.700M	$1.532M
YoY Change	-33.8%	13.33%	5419.53%
TOTAL ASSETS
Total Short-Term Assets	$99.36M	$104.0M	$44.98M
Total Long-Term Assets	$1.409M	$1.700M	$1.532M
Total Assets	$100.8M	$105.7M	$46.51M
YoY Change	-11.25%	127.31%	134.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.054M	$1.000M	$1.248M
YoY Change	-4.82%	-16.67%	202.2%
Accrued Expenses	$690.0K	$600.0K	$328.0K
YoY Change	-3.88%	100.0%	-78.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.830M	$1.600M	$1.662M
YoY Change	-4.22%	-5.88%	-26.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.830M	$1.600M	$1.662M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.800M	$1.600M	$1.700M
YoY Change	-5.26%	-5.88%	-26.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.1M		-$76.56M
YoY Change	35.73%		18.65%
Common Stock	$2.000K		$2.000K
YoY Change	6.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$98.94M	$104.0M	$44.85M
YoY Change
Total Liabilities & Shareholders Equity	$100.8M	$105.7M	$46.51M
YoY Change	-11.25%	127.31%	134.01%

Cashflow Statement

Concept	2016 Q1	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	-$6.884M	-$27.66M	-$4.651M
YoY Change	29.94%	129.83%	-59.56%
Depreciation, Depletion And Amortization	$270.0K	$1.000M	$70.00K
YoY Change	42.11%	900.0%	600.0%
Cash From Operating Activities	-$4.550M	-$18.38M	-$3.310M
YoY Change	-231.55%	-312.91%	47.11%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$1.143M	-$1.420M
YoY Change	-99.74%	-28.2%
Acquisitions
YoY Change
Other Investing Activities	$9.880M	-$90.01M
YoY Change
Cash From Investing Activities	$9.880M	-$71.21M	-$1.420M
YoY Change	-1366.67%	4378.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$68.31M	$32.20M
YoY Change	-100.0%	111.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$78.27M	32.46M
YoY Change	-100.0%	120.72%	48.9%
NET CHANGE
Cash From Operating Activities	-4.550M	-$18.38M	-3.310M
Cash From Investing Activities	9.880M	-$71.21M	-1.420M
Cash From Financing Activities	0.000	$78.27M	32.46M
Net Change In Cash	5.330M	-$11.32M	27.73M
YoY Change	54.11%	-231.14%	41.84%
FREE CASH FLOW
Cash From Operating Activities	-$4.550M	-$18.38M	-$3.310M
Capital Expenditures	$2.000K	$1.143M	-$1.420M
Free Cash Flow	-$4.552M	-$19.52M	-$1.890M
YoY Change	-270.06%	-377.28%	-16.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	314385000	USD
CY2015	dei	Trading Symbol TradingSymbol	LBIO
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48567720	shares
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1630000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13642000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44909000	USD
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	19945000	USD
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	70113000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	277000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	66000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	103977000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	44975000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1676000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1532000	USD
CY2015Q4	us-gaap	Assets Assets	105653000	USD
CY2014Q4	us-gaap	Assets Assets	46507000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	958000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1248000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	586000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	328000	USD
CY2015Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	86000	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	86000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1662000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2015Q4	lbio	Common Stock To Be Issued Value CommonStockToBeIssuedValue	245000	USD
CY2014Q4	lbio	Common Stock To Be Issued Value CommonStockToBeIssuedValue	245000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	48000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207950000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121160000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104222000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76562000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25382000	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44410036	shares
CY2013	us-gaap	Revenues Revenues	0	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	48000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27612000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-25382000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-12035000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	104023000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	44845000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105653000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46507000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2154000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3849000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15470000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	22641000	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2015	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	12041000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	27860000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-22641000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-12041000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-27860000	USD
CY2013	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-445000	USD
CY2014	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6000	USD
CY2015	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	200000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-27660000	USD
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9762513	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24985542	shares
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12035000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	6752000	USD
CY2015	lbio	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	9705000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	255000	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2015	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6752000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	211000	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-32000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18381000	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	19945000	USD
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	140665000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	70600000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1143000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-91153000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9705000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	255000	USD
CY2015	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	48000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2750000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3814000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	70113000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0	USD
CY2015Q4	us-gaap	Trading Securities Cost TradingSecuritiesCost	90010000	USD
CY2015Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	90058000	USD
CY2015	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	48000	USD
CY2015	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	0	USD
CY2015	us-gaap	Depreciation Depreciation	999000	USD
CY2013	us-gaap	Depreciation Depreciation	7000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	782500	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	191500	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	321252	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.04
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.31
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	6.81
CY2014Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32200000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1103000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	104000	USD
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	23300000	USD
CY2014Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6000000	shares
CY2015Q4	lbio	Working Capital WorkingCapital	102300000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.96
CY2014	us-gaap	License Costs LicenseCosts	1400000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9200000	shares
CY2015Q1	us-gaap	Share Price SharePrice	8.00
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	68300000	USD
CY2014Q4	us-gaap	Share Price SharePrice	5.75
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1694	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5694	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1694	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5694	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48547720	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33750188	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48547720	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33750188	shares
CY2015Q4	lbio	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	303125	shares
CY2014Q4	lbio	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	303125	shares
CY2014	lbio	Reclassification Of Stock Based Compensation Cost ReclassificationOfStockBasedCompensationCost	1100000	USD
CY2013	lbio	Reclassification Of Stock Based Compensation Cost ReclassificationOfStockBasedCompensationCost	800000	USD
CY2015	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0	USD
CY2014	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0	USD
CY2013	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	16656000	USD
CY2015	lbio	Cost To Induce Exchange Transaction CostToInduceExchangeTransaction	0	USD
CY2014	lbio	Cost To Induce Exchange Transaction CostToInduceExchangeTransaction	0	USD
CY2013	lbio	Cost To Induce Exchange Transaction CostToInduceExchangeTransaction	2296000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	200000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2741000	USD
CY2015	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2014	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2013	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	8462000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27660000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12035000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33844000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.47
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-11319000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	2559000	USD
CY2014	lbio	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	3222000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	17603000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7126000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23346000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	164000	USD
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-98000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3661000	USD
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Concentrations</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains cash balances at one bank. At times, the amount on deposit exceeds the federally insured limits. Management believes that the financial institution that holds the Company’s cash is financially sound and, accordingly, minimal credit risk exists. As of December 31, 2015 and 2014, the Company’s cash balances were in excess of insured limits maintained at the bank.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In presenting the Company’s statement of operations for the years ended December 31, 2014 and 2013, the Company has reclassified $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font> million, respectively, of stock-based compensation that was previously reflected as general and administrative expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company’s research and development activities, and had no impact on total costs and expenses, or on net loss.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	88000	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	747000	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	999000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19672000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19672000	USD
CY2013	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1771000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	274000	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1255000	USD
CY2015	lbio	Common Stock Issued To Induce Exchange Transaction CommonStockIssuedToInduceExchangeTransaction	0	USD
CY2014	lbio	Common Stock Issued To Induce Exchange Transaction CommonStockIssuedToInduceExchangeTransaction	0	USD
CY2013	lbio	Common Stock Issued To Induce Exchange Transaction CommonStockIssuedToInduceExchangeTransaction	2296000	USD
CY2014	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013	us-gaap	Stock Issued1 StockIssued1	-2003000	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	311000	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	15909000	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	6793000	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2475000	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2559000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-108000	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-608000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8633000	USD
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1592000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1592000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3222000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32240000	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	35462000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25237000	USD
CY2014	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	USD
CY2013Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-100
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	103700000	USD
CY2014Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	44909000	USD
CY2015	lbio	Money Market Funds And Short Terminvestments Weighted Average Time To Maturity MoneyMarketFundsAndShortTerminvestmentsWeightedAverageTimeToMaturity	P66D
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	152	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	157	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	162	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	167	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	638	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12390000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8192000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3831000	USD
CY2013	lbio	Stock Issued During Period Value For Settlement Of Notes Payable And Accrued Liabilities StockIssuedDuringPeriodValueForSettlementOfNotesPayableAndAccruedLiabilities	9268000	USD
CY2013	lbio	Stock Issued During Period Values Issued For Cash StockIssuedDuringPeriodValuesIssuedForCash	1239000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	782500	shares
CY2013	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	0	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2013	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	747000	USD
CY2013	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	16656000	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	274000	USD
CY2013	lbio	Stockissuedduringperiodvaluetodirectors Stockissuedduringperiodvaluetodirectors	2003000	USD
CY2013	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5887000	USD
CY2013	lbio	Preferredstocksoldinprivateplacementvalue Preferredstocksoldinprivateplacementvalue	15909000	USD
CY2013	lbio	Stock Issued During Period Value For Settlement Of Payable StockIssuedDuringPeriodValueForSettlementOfPayable	25000	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1255000	USD
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1771000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	0	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	68307000	USD
CY2015Q4	lbio	Stock Option Shares Outstanding StockOptionSharesOutstanding	2693237	shares
CY2014Q4	lbio	Stock Option Shares Outstanding StockOptionSharesOutstanding	1857877	shares
CY2013Q4	lbio	Stock Option Shares Outstanding StockOptionSharesOutstanding	278750	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7202216	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11084426	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12373156	shares
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	90058000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2779000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1636000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	15000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.04
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.44
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	32200000	USD
CY2015	lbio	Cancellation Of Vested Shares CancellationOfVestedShares	148565	shares
CY2015	lbio	Exchange Transaction Inducement Expense ExchangeTransactionInducementExpense	2200000	USD
CY2013	lbio	Exchange Transaction Inducement Expense ExchangeTransactionInducementExpense	16600000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6700000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2600000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	700000	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	11100000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15300000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8428000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15300000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8428000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.05	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.05	pure
CY2015	lbio	Effectiveincometaxratereconciliationexpectedratetotal1 Effectiveincometaxratereconciliationexpectedratetotal1	-0.39	pure
CY2014	lbio	Effectiveincometaxratereconciliationexpectedratetotal1 Effectiveincometaxratereconciliationexpectedratetotal1	-0.39	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.39	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.39	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	45000000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2013	lbio	Warrant To Aaquired WarrantToAaquired	122734	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y3M
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	32241000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	284748	shares
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.05	pure
CY2013	lbio	Effectiveincometaxratereconciliationexpectedratetotal1 Effectiveincometaxratereconciliationexpectedratetotal1	-0.39	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.39	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Depreciation Depreciation	88000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26633	shares
CY2014Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28271	shares
CY2015	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify"><b><u>NOTE 10. LEGAL PROCEEDINGS</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify">On April 23, 2014, the Company received a subpoena from the Securities Exchange Commission (the “SEC”) that stated that the staff of the SEC is conducting an investigation<i><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> In the Matter of Galena Biopharma, Inc. File No. HO 12356</u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> (now known as “<u>In the Matter of Certain Stock Promotions</u>”)</i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> and that the subpoena was issued to the Company as part of the foregoing investigation. The SEC’s subpoena and accompanying letter did not indicate whether the Company is, or is not, under investigation. We have cooperated with the SEC and have completed our production of documents in response to the subpoena. To date, the SEC has not requested any further information from us. Nevertheless, the SEC may in the future require us to produce additional documents or other materials.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify">The subpoena required us to give the SEC certain documents regarding, and communications between, anyone at this company and certain listed persons and entities (which include investor-relations firms and persons associated with the investor-relations firms), and articles regarding this company posted on certain equity research or other financial websites. We believe that the SEC is investigating improper conduct relative to the payment of bloggers and other authors for promotional articles written about public companies. A number of articles have been written about us that may be available on the internet and elsewhere. Investors considering an investment in our securities should review this Annual Report and the other documents that we filed with the SEC rather than relying on internet blogs or other similar articles and publications.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify">Although we are unaware of the exact scope or timing of the SEC’s investigation, it is our understanding that the investigation is ongoing. We do not know when the investigation will be concluded or to what extent we will be further involved. If we receive additional subpoenas or other requests for documents from the SEC it is our intention to fully cooperate with the SEC. Complying with any such future requests could distract the time and attention of our officers and directors or divert our resources away from research and development programs. Furthermore, we, and our former officers and directors, may be the subject of the SEC’s investigation. Any such investigation could result in significant legal expenses, the diversion of management’s attention from our business, damage to our business and reputation, and could subject us to a wide range of remedies, including an SEC enforcement action and potential financial penalties required by the SEC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0pt 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman', Times, serif; WHITE-SPACE: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal" align="justify">There are no other pending legal proceedings to which the Company is a party or of which its property is the subject.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Revenues Revenues	0	USD
CY2015Q2	us-gaap	Revenues Revenues	0	USD
CY2015Q3	us-gaap	Revenues Revenues	0	USD
CY2015Q4	us-gaap	Revenues Revenues	0	USD
CY2014Q1	us-gaap	Revenues Revenues	0	USD
CY2014Q2	us-gaap	Revenues Revenues	0	USD
CY2014Q3	us-gaap	Revenues Revenues	0	USD
CY2014Q4	us-gaap	Revenues Revenues	0	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-5298000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6367000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-7635000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-8360000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2260000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2110000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3014000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-4651000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37679	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45082	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47272	shares
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47912	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20798	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24138	shares

Files In Submission

Name	View Source	Status
0001144204-16-087506-index-headers.html	Edgar Link	pending
0001144204-16-087506-index.html	Edgar Link	pending
0001144204-16-087506.txt	Edgar Link	pending
0001144204-16-087506-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lbio-20151231.xml	Edgar Link	completed
lbio-20151231.xsd	Edgar Link	pending
lbio-20151231_cal.xml	Edgar Link	unprocessable
lbio-20151231_def.xml	Edgar Link	unprocessable
lbio-20151231_lab.xml	Edgar Link	unprocessable
lbio-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg11.jpg	Edgar Link	pending
tpg8.jpg	Edgar Link	pending
tpg9.jpg	Edgar Link	pending
v432870_10k.htm	Edgar Link	pending
v432870_ex23-1.htm	Edgar Link	pending
v432870_ex31-1.htm	Edgar Link	pending
v432870_ex31-2.htm	Edgar Link	pending
v432870_ex32-1.htm	Edgar Link	pending
v432870_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2016 Q1 Form 10-K Financial Statement

#000114420416087506 Filed on March 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2016 Q1 Form 10-K Financial Statement

#000114420416087506 Filed on March 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova